SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2025

Accounting Policies [Abstract]

SCHEDULE OF UNREALIZED GAINS AND LOSSES

The following table summarizes the cumulative gross unrealized gains and losses and fair values for long-term investments accounted for at fair value under the fair value option, with the unrealized gains and losses reported within earnings on the Condensed Consolidated Statements of Operation as of June 30, 2025 and December 31, 2024:

	Initial Book Value		Cumulative Gross Unrealized Gains		Cumulative Gross Unrealized Losses		Fair Value
June 30, 2025
Investment in GMP Bio (equity securities)	$	22,653,225	$	-	$	-	$	22,653,225
Total	$	22,653,225	$	-	$	-	$	22,653,225

	Initial Book Value		Cumulative Gross Unrealized Gains		Cumulative Gross Unrealized Losses		Fair Value
December 31, 2024
Investment in GMP Bio (equity securities)	$	22,653,225	$	-	$	-	$	22,653,225
Total	$	22,653,225	$	-	$	-	$	22,653,225

SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES

The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of June 30, 2025 and December 31, 2024:

	June 30, 2025 Conversion Feature			December 31, 2024 Conversion Feature
Balance at January 1, 2025 and 2024	$	703,616		$	423,214
Change in fair value		(424,830	)		280,402
Balance at June 30, 2025 and December 31, 2024	$	278,786		$	703,616

SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES

	June 30, 2025 Key Assumptions for fair value of conversions			December 31, 2024 Key Assumptions for fair value of conversions
Risk free interest		3.96	%		3.98%-5.09	%
Market price of share	$	0.04		$	0.02 – 0.04
Life of instrument in years		0.01			0.01
Volatility		139.5	%		138.38%-226.9	%
Dividend yield		0	%		0	%